Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: Osteosarcoma, the most common primary bone tumor, is characterized by an aggressive behavior with high tendency to develop lung metastases as well as by multiple genetic aberrations that have hindered the development of targeted therapies. New therapeutic approaches are urgently needed; however, novel combinations with immunotherapies and checkpoint inhibitors require suitable preclinical models with intact immune systems to be properly tested. Experimental Design: We have developed immunocompetent osteosarcoma models that grow orthotopically in the bone and spontaneously metastasize to the lungs, mimicking human osteosarcoma. These models have been used to test the efficacy of trabectedin, a chemotherapeutic drug utilized clinically for sarcomas and ovarian cancer. Results: Trabectedin, as monotherapy, significantly inhibited osteosarcoma primary tumor growth and lung metastases by both targeting neoplastic cells and reprogramming the tumor immune microenvironment. Specifically, trabectedin induced a striking differentiation of tumor cells by favoring the recruitment of Runx2, the master genetic regulator of osteoblastogenesis, on the promoter of genes involved in the physiologic process of terminal osteoblast differentiation. Differentiated neoplastic cells, as expected, showed reduced proliferation rate. Concomitantly, trabectedin enhanced the number of tumor-infiltrating T lymphocytes, with local CD8 T cells, however, likely post-activated or exhausted, as suggested by their high expression of the inhibitory checkpoint molecule PD-1. Accordingly, the combination with a PD-1–blocking antibody significantly increased trabectedin efficacy in controlling osteosarcoma progression. Conclusions: These results demonstrate the therapeutic efficacy of trabectedin in osteosarcoma treatment, unveiling its multiple activities and providing a solid rationale for its combination with immune checkpoint inhibitors. Clin Cancer Res; 23(17); 5149–61. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 2×
“The involvement of different immune cell subsets in tumor development and progression (6), and their emerging role in the most effective standard (25) or targeted (26) therapeutic treatments for several tumor histotypes, suggest that immunomodulatory drugs represent a potentially appealing therapeutic option, although…”
BackgroundInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508 · cited 3×
“The data on a higher monocytic/macrophagic infiltration in less aggressive, more differentiated tumors might suggest that, differently from other solid tumor histotypes, these cells could be associated with a better prognosis, as described previously (8) and recently confirmed in clinical tissue samples of patients tr…”
BackgroundLussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · cited 1×
“In a subsequent study, the authors reported that combining anti-PD-1 with anti-CTLA-4 antibody prevents tumor immune escape and leads to better disease control (30).”
BackgroundEnhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197 · cited 1×
“Our result of the poor efficacy of anti PD-1 alone appears to contrast with a recent study showing that blockade of the PD-1/ PD-L1 axis is sufficient to reduce growth of the K7M2 osteosarcoma model (29); however, no clear data are shown regarding the overall immune landscape in this model or the number of infiltratin…”
Result
Cited by
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Bailly, C., Thuru, X., & Quesnel, B. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa002 · Cited by 249
“A similar study using immunocompetent models of osteosarcoma also revealed that the combination with a PD-1-blocking antibody significantly increased TBT efficacy in controlling osteosarcoma progression, via an enhancement of the number of tumor-infiltrating T lymphocytes in the tumor microenvironment (96).”
BackgroundLe Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.018 · Cited by 174
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Yang, B., Su, Z., Chen, G., Zeng, Z., Tan, J., Wu, G., Zhu, S., & Lin, L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12441 · Cited by 36
“Therapeutic strategies targeting tumor‑associated macrophages have been demonstrated to significantly suppress metastasis in cases of advanced osteosarcoma (13,14).”
Metadata
- Authors
- Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., Manara, M. C., Bongiovanni, L., Valenti, C. F., Burocchi, A., Parenza, M., Cappetti, B., Sangaletti, S., Tripodo, C., Scotlandi, K., Colombo, M. P., & Chiodoni, C.
- Venue
- Clinical Cancer Research
- Published
- 2017-08-31
- Volume
- 23
- Issue
- 17
- Pages
- 5149-5161
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2624408765
- Cited by
- 90
- References
- 9
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3186
- The paper
- Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., Manara, M. C., Bongiovanni, L., Valenti, C. F., Burocchi, A., Parenza, M., Cappetti, B., Sangaletti, S., Tripodo, C., Scotlandi, K., Colombo, M. P., & Chiodoni, C. (2017). Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.